HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Intravaginal Administration

Subscribe to New Research on Intravaginal Administration

The insertion of drugs into the vagina to treat local infections, neoplasms, or to induce labor. The dosage forms may include medicated pessaries, irrigation fluids, and suppositories.

Also Known As:

Administration, Intravaginal; Vaginal Administration; Administration, Vaginal Drug; Administrations, Intravaginal; Administrations, Vaginal; Administrations, Vaginal Drug; Drug Administrations, Vaginal; Instillations, Vaginal; Intravaginal Administrations; Vaginal Administrations; Vaginal Drug Administrations; Vaginal Instillation; Vaginal Instillations; Administration, Vaginal; Drug Administration, Vaginal; Instillation, Vaginal; Vaginal Drug Administration

Networked: 126 relevant articles (20 outcomes, 14 trials/studies)

Relationship Network

Therapy Context: Research Results

Therapeutics: 15318
- Drug Therapy: 178671
  - Drug Administration Routes: 9
    - Topical Administration: 791
      - Intravaginal Administration: 126

Experts

1.	Labrie, Fernand: 4 articles (11/2015 - 09/2008)
2.	Martel, Céline: 4 articles (11/2015 - 09/2008)
3.	Tang, Oi Shan: 4 articles (08/2009 - 01/2003)
4.	Archer, David F: 3 articles (11/2015 - 01/2015)
5.	Labrie, Claude: 3 articles (05/2015 - 09/2008)
6.	Côté, Isabelle: 3 articles (05/2015 - 09/2008)
7.	Cusan, Leonello: 3 articles (05/2015 - 09/2008)
8.	Peregoudov, Alexandre: 3 articles (01/2009 - 09/2003)
9.	Mittal, Suneeta: 3 articles (01/2009 - 09/2003)
10.	Pretnar-Darovec, Alenka: 3 articles (01/2009 - 09/2003)

Related Diseases

1.	Infection 05/01/2009 - "In a genital infection model using HSV-2-infected mice, FG improved mortality and lesion scores and reduced virus yields by intravaginal administration. " 01/30/2008 - "The results of this study demonstrate that, in the nonhuman primate model, it is possible for vaccine-elicited immune responses to prevent infection after intravaginal administration of virus." 01/05/2006 - "Here we show that vaginal instillation of small interfering RNAs (siRNAs) targeting HSV-2 protects mice from lethal infection. " 12/01/2003 - "Intravaginal administration of herpes simplex virus type 2 to mice leads to infection of several neural and extraneural sites." 03/01/2003 - "We describe here how vaginal administration of the broadly neutralizing human monoclonal antibody b12 can protect macaques from simian-human immunodeficiency virus (SHIV) infection through the vagina. "
2.	Atrophy 12/01/2002 - "While the cyclic administration of oral MPA or transdermic NETA more frequently resulted in endometrial atrophy, the trans-vaginal administration of MP more often induced (p<0.005 at six-month and p <0.001 after 1 year) a functional-like secretive endometrium. " 05/01/2015 - "An objective was to analyze the time course of efficacy of daily intravaginal administration of 0.5% (6.5mg) DHEA (prasterone) for 52 weeks on the moderate to severe (MS) symptoms and signs of vulvovaginal atrophy (VVA). " 01/01/2015 - "The effects of intravaginal administration of dehydroepiandrosterone (DHEA) for the management of symptomatic vulvovaginal atrophy are reviewed. " 01/01/2015 - "Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy." 11/01/2015 - "The objective of the present phase III, placebo-controlled, double-blind, prospective and randomized study was to confirm the efficacy of daily intravaginal administration of 0.50% dehydroepiandrosterone (DHEA; prasterone) ovules for 12 weeks on moderate to severe dyspareunia (or pain at sexual activity) as most bothersome symptom of vulvovaginal atrophy (VVA) while having serum steroid concentrations within normal postmenopausal values. "
3.	Bacterial Vaginosis 07/01/2008 - "Safe and effective long-term vaginal administration of Lactobacillus rhamnosus appears to be a useful complementary approach in the management of bacterial vaginosis." 09/01/2010 - "Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis." 01/01/2009 - "The dominance of lactobacilli in healthy vaginal microbiota and its depletion in bacterial vaginosis (BV) has given rise to the concept of oral or vaginal instillation of probiotic Lactobacillus strains for the management of this condition. " 01/01/2009 - "The data indicate that intravaginal administration of exogenous selected strains of lactobacilli can restore a normal vaginal microbiota and be used in treating bacterial vaginosis." 09/01/2010 - "In summary, five days of vaginal administration of LN strains after conventional treatment of bacterial vaginosis and/or vulvovaginal candidiasis lead to vaginal colonization, somewhat fewer recurrences and less malodorous discharge."
4.	Herpes Genitalis (Genital Herpes) 05/01/2001 - "Intravenous but not vaginal administrations of bmDC pulsed in vitro with UV-inactivated HSV-2, or with purified HSV-2 envelope glycoproteins gave rise to complete protection against disease, as well as death caused by genital herpes infection. " 12/01/2003 - "Unformulated SPL7013 provided significant protection from genital herpes disease and infection at concentrations as low as 1 mg/ml and for at least 1 h following topical (intravaginal) administration of 10 mg/ml. This compound was then formulated into three vehicles and further evaluated in mouse and guinea pig models of genital herpes infection. " 08/18/2005 - "Design of a liposome delivery system for vaginal administration of acyclovir, able to provide sustained release and improved bioavailability of the encapsulated drug for the local treatment of genital herpes was investigated. " 06/01/2008 - "Our laboratory and others have shown recently that activation of TLR/MyD88 signaling through vaginal administration of CpG oligodeoxynucleotides, either singly or in combination with recombinant glycoprotein from herpes simplex virus type 2 (HSV-2), confers immunity against genital herpes infection. "
5.	Pain (Aches) 06/01/2011 - "The study was aimed to evaluate the effectiveness, outcome, and pain intensity of the vaginal administration of misoprostol for the induction of abortion between 13 and 24 gestational weeks. " 07/01/2014 - "Vaginal administration of 0.5-mg nitroglycerin gel 30 min prior to IUD placement does not appear to decrease patient-reported procedural pain among nulliparous women or ease of insertion for providers." 07/01/1981 - "Most of these drawbacks seem to be overcome when prostaglandin analogues are used; however, vaginal administration caused appreciable pain in 10-30% of women, and so severely limits self-administration of these analogues. " 05/01/1957 - "[Intravaginal administration of ether for pain induction in obstetrics]." 07/01/2009 - "This study was to investigate analgesic effect of vaginal administration of controlled-release oxycodone on cancer pain and observe adverse events to provide a new choice for female patients who can not tolerate the adverse events caused by oral administration. "

Related Drugs and Biologics

1.	Dehydroepiandrosterone (DHEA)
2.	Small Interfering RNA (siRNA)
3.	Liposomes (Liposome)
4.	Progesterone
5.	Misoprostol (Cytotec)
6.	Metronidazole (Metric)
7.	Estriol (Epiestriol)
8.	Hormones
9.	Estrogens (Estrogen)
10.	imidazole

Related Therapies and Procedures

1.	Hysterectomy
2.	Oral Administration
3.	Curettage
4.	Self Administration (Administration, Self)
5.	Chemoprevention